Aurobindo’s $250M Lannett Buy Adds 4B Dose Capacity, FTC OKs

For healthcare providers and systems, this acquisition signals a significant expansion in the supply of complex generic drugs, particularly non-opioid controlled substances—critical for managing pain without addiction risks. The addition of Lannett's 4 billion dose annual capacity in Indiana directly supports US efforts to reduce reliance on foreign manufacturing and ensure stable access to these therapies. Here's what the Aurobindo-Lannett deal means for drug availability, pricing dynamics, and regulatory alignment in American healthcare.

Aurobindo Pharma’s U.S. subsidiary, Aurobindo Pharma USA, Inc., has cleared the final regulatory hurdle for its $250 million acquisition of Lannett Company LLC, with the U.S. Federal Trade Commission (FTC) granting approval on June 22, 2026. The deal, expected to close by the end of June, is structured on a cash-free, debt-free basis and includes normalized working capital. It marks a significant expansion for Aurobindo in the lucrative U.S. generic pharmaceuticals market, particularly in the niche of complex, non-opioid controlled substances—a segment that has gained prominence amid the opioid crisis and policy shifts toward domestic manufacturing.

“

subsidiary, Aurobindo Pharma USA, Inc., has cleared the final regulatory hurdle for its $250 million acquisition of Lannett Company LLC, with the U.S.

Lannett, a Pennsylvania-based company that emerged from Chapter 11 restructuring as a private LLC, brings a specialized portfolio and a key manufacturing asset: a facility in Seymour, Indiana, capable of scaling production to approximately 4 billion doses annually. This capacity will substantially augment Aurobindo’s existing U.S. manufacturing footprint, which is strategically aligned with Washington’s emphasis on supply chain resilience and reducing dependence on imported pharmaceuticals. The acquisition is expected to be immediately accretive to Aurobindo Group’s earnings per share, a rare attribute for deals of this size in the generics sector, indicating the underlying profitability and operational leverage of Lannett’s assets.

From a strategic standpoint, the transaction addresses several of Aurobindo’s long-term objectives. First, it diversifies its product portfolio into complex generics and controlled substances—therapies with higher barriers to entry due to technical manufacturing challenges and regulatory scrutiny, but which command better margins and face less commoditization than simple generics. Second, it provides a ready-to-scale domestic manufacturing base that can serve as a launchpad for future product launches and potentially mitigate tariff or trade disruption risks. Third, the integration is expected to generate meaningful cost efficiencies, including SG&A synergies, which can bolster margins in a pricing environment that remains challenging for many generic drugmakers.

The deal also underscores a broader trend of Indian pharmaceutical companies consolidating their U.S. presence through targeted acquisitions, rather than solely organic growth. Aurobindo’s move follows similar strategic plays by peers like Sun Pharma and Cipla, who have also sought to enhance their controlled substance capabilities or niche portfolios. For the U.S. healthcare system, the infusion of capacity for non-opioid pain medications is particularly relevant as providers and payers seek alternatives to opioids. The acquisition’s emphasis on non-opioid controlled substances—such as certain CNS drugs—aligns with public health priorities and could improve access to these therapies.